Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.anai.2018.09.467 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Global burden of disease attributable to metabolic risk factors in adolescents and young adults aged 15-39, 1990-2021.
Clin Nutr
December 2024
MAFLD Research Center, Department of Hepatology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China; Key Laboratory of Diagnosis and Treatment for the Development of Chronic Liver Disease in Zhejiang Province, Wenzhou, China. Electronic address:
Background: Metabolic risk factors are a significant cause of global burden among adolescents and young adults, but there is a lack of attention to the burden attributable to these metabolic risk factors globally.
Aims: This study aims to provide comprehensive estimates of five important metabolic risk factors and the attributable disease burden in people aged 15-39 years from 1990 to 2021, based on the Global Burden of Disease Study (GBD) database.
Methods: Global total deaths and disability-adjusted life years (DALYs) were used to describe the burden attributable to five common metabolic risk factors, including high fasting plasma glucose (FPG), high low-density lipoprotein cholesterol (LDL-C), high systolic blood pressure (SBP), high body mass index (BMI), and kidney dysfunction, in adolescents and young adults.
Characteristic features of food allergy to legumes: From epidemiology to prevention.
Hum Immunol
November 2024
Department of Allergology, National Medical Institute of the Ministry of the Interior and Administration, Warsaw, Poland. Electronic address:
Article Synopsis
- - The study explores food allergies related to legumes (such as peanuts, chickpeas, and soybeans), revealing that about 10% of people with allergic diseases have food allergies, with prevalence rates varying by legume type.
- - In Poland, around 5% of the population is affected by food allergies, with peanuts identified as the most allergenic, alongside notable sensitization rates for other legumes like soy and lentils.
- - The diagnosis involves various tests, and treatment may include emergency epinephrine and allergen immunotherapy, highlighting the need for better understanding and management of these allergies due to their potential severity.
Objectives: To assess the efficacy and safety of the non-hormonal, neurokinin 3 receptor antagonist, fezolinetant, to treat moderate-severe vasomotor symptoms associated with menopause in individuals unsuitable for hormone therapy.
Design: Phase 3b randomised controlled trial.
Setting: 16 countries.
Plant growth regulators improve the yield of white lupin (Lupinus albus) by enhancing the plant morpho-physiological functions and photosynthesis under salt stress.
BMC Plant Biol
October 2024
La Trobe Institute of Sustainable Agriculture and Food (LISAF), Department of Animal, Plant and Soil Sciences, AgriBio, La Trobe University, Melbourne, 3086, Australia.
Background: White lupin (Lupinus albus L.) is a multi-purpose, climate resilient, pulse crop with exceptionally high protein content that makes it a suitable alternative of soybean in livestock feed. Although white lupin grows well on marginal sandy soils, previous studies have reported its sensitivity towards salinity stress.
View Article and Find Full Text PDFEfficacy of xanomeline and trospium chloride in schizophrenia: pooled results from three 5-week, randomized, double-blind, placebo-controlled, EMERGENT trials.
Schizophrenia (Heidelb)
November 2024
Bristol Myers Squibb, Princeton, NJ, USA.
In the 5-week, randomized, double-blind, placebo-controlled EMERGENT-1 (NCT03697252), EMERGENT-2 (NCT04659161), and EMERGENT-3 (NCT04738123) trials, xanomeline and trospium chloride (formerly known as KarXT) significantly improved symptoms of schizophrenia and was generally well tolerated. We pooled data from the EMERGENT trials to further characterize the efficacy of xanomeline/trospium and provide sufficient statistical power to analyze responses in participant subgroups. In pooled analyses, xanomeline/trospium significantly improved Positive and Negative Syndrome Scale (PANSS) total score at week 5 versus placebo (least squares mean difference, -9.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!